Intas CEO expects to break into U.S. biosimilar market yet this year

Eric Palmer

The CEO of Pharmaceuticals his company to get FDA approval for its of Amgen's Neulasta, a drug it developed with Canada's Apotex.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS